Enhanced brain drug delivery: safely crossing the blood–brain barrier

Gaillard, Pieter J.; Visser, Corine C.; Appeldoorn, Chantal C.M.; Rip, Jaap

doi:10.1016/j.ddtec.2011.12.002

Cited by 41 publications

(50 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The total ribavirin concentration was measured, i.e., the liposomal encapsulated ribavirin and the free ribavirin Many strategies have been developed to increase drug delivery to the brain, which can also be used together with liposomal drug delivery. These have been extensively discussed previously (Jones and Shusta 2007 ;Rip et al 2010 ;Gaillard et al 2011 ), as well as within this book (Gabathule 2014 ). Targeting ligands will not only alter the pharmaceutical properties of the liposomes but also infl uence their biodistribution.…”

Section: Liposomesmentioning

confidence: 97%

“…Is there a prolonged circulation because of pegylation? Even if the answers are already known for the free drug, it is important to determine them for the nanocarrier encapsulated drug as well, as this will most likely infl uence the drug's disposition in the body (Gaillard et al 2011 ;Nystrom and Fadeel 2012 ) and in the brain. In addition to the PK and biodistribution, the effi cacy of brain delivery as well as the effi cacy of the encapsulated drug needs to be determined.…”

Section: Pharmacologymentioning

confidence: 99%

“…In general, by choosing the right constituents, liposomes are regarded as safe nanocarriers. Besides the more general "nanocarrier advantages" such as prolonged circulation time, liposomes have the additional benefi t that they can encapsulate both lipophilic and hydrophilic compounds ranging from small molecules to larger biological compounds without modifi cation of the encapsulated active pharmaceutical ingredient (API) (Gaillard et al 2011 ).…”

Section: Liposomesmentioning

confidence: 99%

“…15.1 ). Recently, we have summarized these aspects in ten key development criteria for targeted blood-to-brain drug delivery (Gaillard 2010 ;Gaillard et al 2011 ). Of the currently active developments, only two brain-targeted delivery-based therapies have been approved for clinical research, i.e., Angiopep-2 conjugated to paclitaxel (ANG1005/GRN1005; based on the EPiC Technology) and glutathione pegylated liposomal doxorubicin (2B3-101; based on the G-Technology).…”

mentioning

confidence: 99%

“…Turning one wheel will infl uence the whole development process. CMC chemistry, manufacturing, and controls them to our ten key development criteria (Gaillard et al 2011 ). In this book chapter we will focus on the pharmaceutical, pharmacological, and regulatory aspects of the development of nanocarriers for blood-to-brain drug delivery.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Blood-to-Brain Drug Delivery Using Nanocarriers

Gaillard¹,

Visser²,

Boer³

et al. 2013

AAPS Advances in the Pharmaceutical Sciences Series

Self Cite

View full text Add to dashboard Cite

Brain and nervous system disorders represent a large, unmet medical need affecting two billion people worldwide; a number that is expected to grow with increasing life expectancy and the expanding global population. CNS drug development is hampered by the restricted transport of drug candidates across the bloodbrain barrier (BBB). We will discuss blood-to-brain drug delivery strategies that make use of nanocarriers, like liposomes, albumin nanoparticles, and polymeric nanoparticles. The focus will be on the key pharmaceutical, pharmacological, and regulatory aspects towards the clinical development of nanocarriers. Clinical development of treatments employing nanocarriers is not as straightforward as for a single active moiety; therefore, we will highlight the issues that should be considered when translating basic research towards clinical development. Although it is still unrealistic to expect a magic bullet for exclusive CNS drug delivery, much progress has been made towards successful development of novel treatments for patients with devastating brain diseases.

show abstract

Section: Liposomesmentioning

confidence: 97%

Section: Pharmacologymentioning

confidence: 99%

Section: Liposomesmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations